Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

Change of Quality of Life in Children with ADHD after 12 Weeks OROS-Methylphenidate Treatment

12주 OROS-Methylphenidate 약물 치료 후 ADHD 아동의 삶의 질 변화

  • Kim, Hyung-In (Department of Psychiatry, Seoul National University Hospital) ;
  • Kim, Bung-Nyun (Department of Psychiatry, Seoul National University Hospital) ;
  • Cho, Soo-Churl (Department of Psychiatry, Seoul National University Hospital) ;
  • Shin, Min-Sup (Department of Psychiatry, Seoul National University Hospital) ;
  • Yoo, Hee-Jeong (Department of Psychiatry, Seoul National University Bundang Hospital) ;
  • Kim, Jae-Won (Department of Psychiatry, Seoul National University Hospital) ;
  • Kim, Ji-Hoon (Department of Psychiatry, Pusan National University Hospital) ;
  • Son, Jung-Woo (Department of Psychiatry, Chungbuk National University Hospital) ;
  • Shin, Yun-Mi (Department of Psychiatry, Ajou University Hospital) ;
  • Chung, Un-Sun (Department of Psychiatry, Kyungpook National University Hospital) ;
  • Han, Doug-Hyun (Department of Psychiatry, Chung-Ang University Hospital)
  • 김형인 (서울대학교병원 정신건강의학과) ;
  • 김붕년 (서울대학교병원 정신건강의학과) ;
  • 조수철 (서울대학교병원 정신건강의학과) ;
  • 신민섭 (서울대학교병원 정신건강의학과) ;
  • 유희정 (분당서울대학교병원 정신건강의학과) ;
  • 김재원 (서울대학교병원 정신건강의학과) ;
  • 김지훈 (부산대학교병원 정신건강의학과) ;
  • 손정우 (충북대학교병원 정신건강의학과) ;
  • 신윤미 (아주대학교병원 정신건강의학과) ;
  • 정운선 (경북대학교병원 정신건강의학과) ;
  • 한덕현 (중앙대학교병원 정신건강의학과)
  • Received : 2012.08.01
  • Accepted : 2012.09.04
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The aim of this study is to investigate the effectiveness of treatment with osmotic-release oral system methylphenidate (OROS-MPH) on quality of life (QOL) in children with attention-deficit hyperactivity disorder (ADHD). Another aim is to assess the relationship between change in QOL and other factors including children's symptoms and academic performance or parents' depression and parenting stress. Methods : A total of 111 medication-naive children with ADHD in a multicenter, open-label, 12-week trial of OROS-MPH completed an evaluation using diverse rating scales at two time points; at baseline and after 12 weeks of treatment. Scales for investigation of children included the Parent Report Form-Children's Health and Illness Profile-Children's Edition (PRF-CHIP-CE) on QOL, the ADHD Rating Scale-IV on symptoms, and the Academic Performance Rating Scale (APRS). The Beck Depression Inventory and Parenting Stress Index were used for assessment of their parents. Results : Total scores for mean PRF-CHIP-CE increased from $207.9{\pm}26.7$ at baseline to $226.3{\pm}25.9$ after 12 weeks of treatment (p<.001). The change of APRS showed the strongest correlation with the increment of PRF-CHIP-CE scores (Pearson coefficient=0.561, p<.001), even after controlling for other factors (partial correlation coefficient=0.420, p<.001). Conclusion : Treatment with MPH-OROS results in improvement of QOL in children with ADHD in Korea. The advance in academic performance plays a key role in this change of QOL.

Keywords

References

  1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-948. https://doi.org/10.1176/appi.ajp.164.6.942
  2. Johnston C, Mash EJ. Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 2001;4:183-207. https://doi.org/10.1023/A:1017592030434
  3. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-948. https://doi.org/10.1176/appi.ajp.164.6.942
  4. Riley AW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G; ADORE Study Group. Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition. Eur Child Adolesc Psychiatry 2006;15 Suppl 1: I63-I71. https://doi.org/10.1007/s00787-006-1009-6
  5. Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I. Worse quality of life for children with newly diagnosed attention- deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 2005;116:e364-e369. https://doi.org/10.1542/peds.2005-0386
  6. Sawyer MG, Whaites L, Rey JM, Hazell PL, Graetz BW, Baghurst P. Health-related quality of life of children and adolescents with mental disorders. J Am Acad Child Adolesc Psychiatry 2002;41:530-537. https://doi.org/10.1097/00004583-200205000-00010
  7. Dopfner M, Steinhausen HC, Coghill D, Dalsgaard S, Poole L, Ralston SJ, et al. Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study. Eur Child Adolesc Psychiatry 2006;15 Suppl 1:I46-I55. https://doi.org/10.1007/s00787-006-1007-8
  8. Coghill D, Danckaerts M, Sonuga-Barke E, Sergeant J; ADHD European Guidelines Group. Practitioner review: Quality of life in child mental health--conceptual challenges and practical choices. J Child Psychol Psychiatry 2009;50:544-561. https://doi.org/10.1111/j.1469-7610.2009.02008.x
  9. Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Döpfner M, Hollis C, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry 2010;19:83-105. https://doi.org/10.1007/s00787-009-0046-3
  10. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 2009;29:656-679. https://doi.org/10.1592/phco.29.6.656
  11. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003;42:424-433. https://doi.org/10.1097/01.CHI.0000046814.95464.7D
  12. Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur Child Adolesc Psychiatry 2010;19:325-340. https://doi.org/10.1007/s00787-009-0056-1
  13. Mattos P, Louza MR, Palmini AL, Oliveira IR, Rocha FL. A Multicenter, Open-Label Trial to Evaluate the Quality of Life in Adults With ADHD Treated With Long-Acting Methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) Study. J Atten Disord In Press 2012.
  14. Riley AW, Spiel G, Coghill D, DÖpfner M, Falissard B, Lorenzo MJ, et al. Factors related to health-related quality of life (HRQoL) among children with ADHD in Europe at entry into treatment. Eur Child Adolesc Psychiatry 2006;15 Suppl 1:I38-I45.
  15. Klassen AF, Miller A, Fine S. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Pediatrics 2004;114:e541-e547. https://doi.org/10.1542/peds.2004-0844
  16. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005;44:240-248. https://doi.org/10.1097/00004583-200503000-00008
  17. Gurkan K, Bilgiç A, Türkoglu S, Kiliç BG, Aysev A, Uslu R. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. J Psychopharmacol 2010;24:1810-1818. https://doi.org/10.1177/0269881109348172
  18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association;2000.
  19. Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version- Korean version (K-SADS-PL-K). Yonsei Med J 2004;45:81-89. https://doi.org/10.3349/ymj.2004.45.1.81
  20. Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care 2004;42:210-220. https://doi.org/10.1097/01.mlr.0000114909.33878.ca
  21. So YK, Noh JS, Kim YS, Ko SG, Koh YJ. The reliability and validity of Korean parent and teacher ADHD Rating Scale. J Korean Neuropsychiatr Assoc 2002;41:283-289.
  22. Cho YK, Ha EH. Validation study of the Korean Academic Performance Rating Scale (K-APRS) Parent Form. Korean J Clin Psychol 2009;28:1173-1189. https://doi.org/10.15842/kjcp.2009.28.4.012
  23. Han HM, Yeom TH, Shin YW, Kim GH, Yoon DJ, Chung KJ. A standardization study of Beck Depression Inventory in Korea: For normal group (1). J Korean Neuropsychiatr Assoc 1986;25:487-500.
  24. Chung MJ, Shin SJ. Effects of stress, social support and efficacy on Mothers' parenting behaviors. Child Stud Diverse Contexts 1998;19: 27-42.
  25. Wallander JL, Schmitt M, Koot HM. Quality of life measurement in children and adolescents: issues, instruments, and applications. J Clin Psychol 2001;57:571-585. https://doi.org/10.1002/jclp.1029
  26. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000;9:887-900. https://doi.org/10.1023/A:1008996223999
  27. Yoo HK, Park S, Wang HR, Lee JS, Kim K, Paik KW, et al. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system. Epileptic Disord 2009;11:301-308.
  28. Escobar R, Montoya A, Polavieja P, Cardo E, Artigas J, Hervas A, et al. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19: 253-263. https://doi.org/10.1089/cap.2008.0109
  29. Svanborg P, Thernlund G, Gustafsson PA, Hagglof B, Schacht A, Kadesjo B. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry 2009;18:725-735. https://doi.org/10.1007/s00787-009-0031-x
  30. Green CT, Long DL, Green D, Iosif AM, Dixon JF, Miller MR, et al. Will Working Memory Training Generalize to Improve Off-Task Behavior in Children with Attention-Deficit/Hyperactivity Disorder? Neurotherapeutics In Press 2012.

Cited by

  1. A Validation Study of Child Health-6 Dimension (CH-6D), a Generic Preference-Based Health-Related Quality of Life Measure vol.22, pp.1, 2018, https://doi.org/10.21896/jksmch.2018.22.1.53
  2. The Influence of Depression and School Life on the Quality of Life of Korean Child and Adolescent Patients with Attention-Deficit/Hyperactivity Disorder: A Comparison of the Perspectives of the Patien vol.30, pp.1, 2012, https://doi.org/10.5765/jkacap.180027
  3. A Brief Replication Study Comparing Stimulants and Non-Stimulants for Attention-Deficit/Hyperactivity Disorder Treatment with a Focus on the Compliance, Efficacy, and Satisfaction vol.32, pp.1, 2012, https://doi.org/10.5765/jkacap.200024